Beijing Beilu Pharmaceutical Co., Ltd Reports Earnings Results for the First Quarter Ended March 31, 2022
April 27, 2022 at 04:41 am EDT
Share
Beijing Beilu Pharmaceutical Co., Ltd reported earnings results for the first quarter ended March 31, 2022. For the first quarter, the company reported sales was CNY 183.93 million compared to CNY 222.08 million a year ago. Revenue was CNY 183.93 million compared to CNY 222.08 million a year ago. Net income was CNY 39.26 million compared to CNY 50.45 million a year ago. Basic earnings per share from continuing operations was CNY 0.08 compared to CNY 0.1032 a year ago.
Beijing Beilu Pharmaceutical Co., Ltd is a China-based company principally engaged in the research, development, production and distribution of contract medium products, anti-diabetic products and anti-anxiety products. The Companyâs main products include gadopentetate dimeglumine injection, iohexol injection, Iodoparol injection, Iodixanol injection, ferric ammonium citrate effervescent granules, repaglinide tablets, glimepiride tablets, Jiuwei Zhenxin granules, among others. The Company mainly distributes its products in domestic market.